Fundz

Fundz Deep Dive

Everything you need to win Alan Saghatelian — in one platform.

Who to reach, what to say, and why now on Alan Saghatelian — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Alan Saghatelian — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Velia Therapeutics Appoints Alan Saghatelian As Chief Technology Officer

PRIVATEAug 12, 2024•almost 2 years ago

Position

Chief Technology Officer

Company

Velia Therapeutics

Alan Saghatelian
San DiegoBiotechnology

Description

Velia Therapeutics has announced the appointment of Alan Saghatelian, PhD, as the chief technology officer. Dr. Saghatelian, a scientific co-founder of Velia Therapeutics, will oversee critical development activities to optimize the company’s proprietary microprotein-based platform and advance its robust pipeline of novel therapeutics.

Company Information

Company

Velia Therapeutics

Location

San Diego, California, United States

About

Velia Therapeutics is a biotechnology company focused on the discovery and development of a new generation of protein-based therapeutics that address the underlying causes of difficult-to-treat diseases. The company is the scientific leader in identifying disease-relevant microproteins hidden in the dark matter of the human proteome. Harnessing its proprietary platform technology and unique expertise in microprotein discovery, Velia is focused on uncovering new drug targets and developing first-in-class therapies for renal, inflammatory and immunologic disorders and other diseases. The company’s innovative technology for identifying novel protein coding sequences in the proteome is based upon the seminal work of its world-renowned scientific founders, Eric Olson, PhD, Alan Saghatelian, PhD, Richard Scheller, PhD, and Jonathan Weissman, PhD; all recognized leaders in protein biology. Led by an experienced management team and funded by top-tier venture groups, the company is poised to break new ground in protein-based therapeutics to transform medical care and improve patients’ lives.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Velia Therapeutics's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.